According to a filing with the Hong Kong Stock Exchange on August 20, Bonasia (Hangzhou) Pharmaceutical Technology Co., Ltd. (referred to as "Bonasia") has submitted a listing application for the Main Board, with China Industrial Securities International and ICBC International serving as joint sponsors. The company previously filed with the exchange on February 11, 2026.

Company Overview

According to the prospectus, Bonasia is a clinical contract research organization headquartered in Hangzhou, China, dedicated to advancing clinical research through digital empowerment. Clinical CRO services generally cover various stages of pharmaceutical clinical studies, including clinical trial technical services deliverable on a project-based or FSP model, site management, data management, and biostatistical analysis. The company's core business involves providing clinical trial technical services to domestic and international pharmaceutical and biotech companies, aiming to accelerate the R&D and commercialization of chemical drugs and biologics. In 2025, among companies headquartered in China, the company ranked 14th by revenue from clinical CRO services, holding a 0.7% market share.

The company's clinical CRO services primarily concentrate on clinical trial technical services, spanning the entire clinical development process, including Investigational New Drug applications, Phase I-IV clinical studies, New Drug Application registrations, as well as FSP services and other offerings. Headquartered in Hangzhou, the company operates more than 20 teams across major Chinese cities, including Beijing, Shanghai, Guangzhou, Hangzhou, and Wuhan, serving key clinical research institutions and diverse patient populations nationwide. Additionally, the company has subsidiaries and localized teams in the United States and Australia. Its overseas teams possess expertise in both China-US IND filings and early-stage clinical development, conducting international multi-center clinical trials through strategic partnerships with established collaborators in Europe and the US.

The company's client base includes over 200 innovative pharmaceutical and biotech companies, including numerous top 50 companies by sales revenue in China, such as Buchang Pharmaceutical and Guangzhou Baiyunshan Pharmaceutical. As of June 30, 2026, the top five clients by revenue during each year or period of the track record maintained an average partnership of over six years, with several clients maintaining relationships exceeding a decade.

Financial Highlights

Revenue for the fiscal years 2023, 2024, 2025, and the six months ended June 30, 2026, reached approximately RMB 371 million, RMB 340 million, RMB 336 million, and RMB 204 million, respectively.

Gross profit for the same periods was approximately RMB 124 million, RMB 130 million, RMB 131 million, and RMB 71 million, with gross margins of 33.5%, 38.3%, 38.9%, and 35.0%, respectively.

Profit for the years or periods recorded approximately RMB 47 million, RMB 58 million, RMB 52 million, and RMB 22 million for 2023, 2024, 2025, and the first half of 2026, respectively.

Industry Landscape

The global pharmaceutical industry expanded from approximately USD 1,298.8 billion in 2020 to USD 1,615 billion in 2025, with projections to reach USD 2,507.3 billion by 2034, reflecting a compound annual growth rate of 5.0% from 2025 to 2034. Based on patent status and product exclusivity, the global pharmaceutical market can be broadly divided into innovative drugs, generics, and biosimilars. In 2025, innovative drugs accounted for a market size of USD 1,126.6 billion, while generics and biosimilars reached USD 488.4 billion. From 2025 to 2034, innovative drugs are projected to grow at a CAGR of 5.3%, exceeding that of generics and biosimilars, reaching USD 1,797.4 billion by 2034 and representing over 70% of the global pharmaceutical market.

China's pharmaceutical industry grew significantly from approximately RMB 1,447.9 billion in 2020 to approximately RMB 1,654.6 billion in 2025, with expectations to reach RMB 2,811.4 billion by 2034, achieving a CAGR of 6.1% from 2025 to 2034. Innovative drugs are anticipated to become the primary growth driver, with a CAGR of 10.3% from 2025 to 2034, substantially outpacing generics and biosimilars and driving a continued structural shift toward innovation. As China's pharmaceutical industry enters a phase of high-quality development, R&D innovation will receive increasing government support and pharmaceutical company attention.

China's pharmaceutical R&D expenditure presents significant growth potential. In 2025, total pharmaceutical R&D spending in China reached RMB 280.5 billion, with projections to continue growing to RMB 951.8 billion by 2034, representing a CAGR of 14.5%. The Chinese CRO services market comprises three primary segments: drug discovery services, preclinical CRO services, and clinical CRO services, with clinical CRO services representing the largest portion at over 50% of the entire market. In 2025, China's clinical CRO services market was valued at RMB 48 billion, with projections to reach RMB 91 billion and RMB 140.4 billion by 2030 and 2034, respectively, reflecting a CAGR of 12.8% from 2020 to 2025 and 12.7% from 2025 to 2034. As China's innovative drug industry matures, the clinical CRO market is expected to expand further.

In 2025, the global clinical CRO services market was valued at USD 62.2 billion, with projections to grow to USD 128.3 billion by 2034, representing a CAGR of 8.4%. China's clinical CRO services market was valued at USD 6.7 billion in 2025, expected to reach USD 19.5 billion by 2034, achieving a CAGR of 12.7%. With China's expanding innovative drug pipeline and increasing demand for clinical development outsourcing, the country's clinical CRO services market is expected to grow at a higher rate than the global market and other regions during the forecast period.

Board and Management Information

The company's board consists of seven directors, including three executive directors, one non-executive director, and three independent non-executive directors. Directors serve three-year terms and are eligible for re-election upon expiration.

Shareholding Structure

As of the latest practicable date (August 10, 2026), Mr. Zhao, the controlling shareholder, directly holds 57.28% of the company's shares. Additionally, as the general partner and executive partner of Boda Innovation and Bohua Innovation, Mr. Zhao indirectly holds 12.70% and 4.23% of the shares, respectively.

Advisory Team

Joint sponsors: China Industrial Securities International Capital Limited and ICBC International Capital Limited. Legal advisors: King & Wood Mallesons for Hong Kong law and Zhong Lun Law Firm for Chinese law. Joint sponsor and legal advisors: DeHeng Law Offices for Chinese law. Auditor and reporting accountant: KPMG. Industry consultant: Frost & Sullivan (Beijing) Consulting Co., Ltd. Shanghai Branch.